Table 4.
Prevalence of LMM, LMS and LPF under different diagnostic criteria
| LMM | LMS | LPF | Sarcopenia | |
|---|---|---|---|---|
| AWGS 2019 | 172 (17.0%) | 145 (14.4%) | 160 (15.9%) | 87 (8.6%) |
| EWGSOP 2 | 172 (17.0%) | 121 (12%) | 75 (7.4%) | 54 (5.4%) |
| AWGS 2014 | 172 (17.0%) | 100 (9.9%) | 75 (7.4%) | 60 (5.9%) |
| EWGSOP 1 | 293 (29.0%) | 198 (19.6%) | 75 (7.4%) | 123 (12.2%) |
| IWGS | 293 (29.0%) | – | 160 (15.9%) | 87 (8.6%) |
| FNIH | 198 (19.6%) | 100 (9.9%) | 75 (7.4%) | 23 (2.3%) |
| χ2 | 105.72 | 58.02 | 103.86 | 88.15 |
| P value | < 0.001* | < 0.001* | < 0.001* | < 0.001* |
LMM low muscle mass, LMS low muscle strength, LPF low physical function, AWGS Asian Working Group for Sarcopenia, EWGSOP European Working Group on Sarcopenia in Older People, IWGS the International Working Group on Sarcopenia, FNIH the Foundation for the National Institutes of Health
*P < 0.05